vs
Side-by-side financial comparison of AGENUS INC (AGEN) and ARGENX SE (ARGX). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $34.2M, roughly 72.3× AGENUS INC). ARGENX SE runs the higher net margin — 35.5% vs -31.0%, a 66.5% gap on every dollar of revenue. On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs 27.5%).
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
AGEN vs ARGX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $34.2M | $2.5B |
| Net Profit | $-10.6M | $877.2M |
| Gross Margin | — | 89.5% |
| Operating Margin | 42.1% | 28.9% |
| Net Margin | -31.0% | 35.5% |
| Revenue YoY | 27.5% | 83.2% |
| Net Profit YoY | 77.3% | 1.3% |
| EPS (diluted) | $0.09 | $13.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.2M | $2.5B | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $25.7M | $1.8B | ||
| Q1 25 | $24.1M | — | ||
| Q4 24 | $26.8M | $1.4B | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $23.5M | $901.9M | ||
| Q1 24 | $28.0M | — |
| Q4 25 | $-10.6M | $877.2M | ||
| Q3 25 | $63.9M | — | ||
| Q2 25 | $-30.0M | $414.8M | ||
| Q1 25 | $-26.4M | — | ||
| Q4 24 | $-46.8M | $865.6M | ||
| Q3 24 | $-67.2M | — | ||
| Q2 24 | $-54.8M | $-32.5M | ||
| Q1 24 | $-63.5M | — |
| Q4 25 | — | 89.5% | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | 89.2% | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | 90.2% | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | 89.4% | ||
| Q1 24 | 99.6% | — |
| Q4 25 | 42.1% | 28.9% | ||
| Q3 25 | -15.0% | — | ||
| Q2 25 | -65.0% | 19.2% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -96.5% | 8.7% | ||
| Q3 24 | -125.5% | — | ||
| Q2 24 | -128.4% | -15.4% | ||
| Q1 24 | -117.4% | — |
| Q4 25 | -31.0% | 35.5% | ||
| Q3 25 | 211.4% | — | ||
| Q2 25 | -116.8% | 23.4% | ||
| Q1 25 | -109.6% | — | ||
| Q4 24 | -174.4% | 64.1% | ||
| Q3 24 | -267.7% | — | ||
| Q2 24 | -233.1% | -3.6% | ||
| Q1 24 | -226.6% | — |
| Q4 25 | $0.09 | $13.25 | ||
| Q3 25 | $1.94 | — | ||
| Q2 25 | $-1.00 | $6.32 | ||
| Q1 25 | $-1.03 | — | ||
| Q4 24 | $-1.95 | $13.33 | ||
| Q3 24 | $-3.08 | — | ||
| Q2 24 | $-2.52 | $-0.55 | ||
| Q1 24 | $-3.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $3.5B |
| Total DebtLower is stronger | $44.7M | — |
| Stockholders' EquityBook value | $-271.1M | $7.3B |
| Total Assets | $226.8M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $3.5B | ||
| Q3 25 | $3.5M | — | ||
| Q2 25 | $9.5M | $2.1B | ||
| Q1 25 | $18.5M | — | ||
| Q4 24 | $40.4M | $1.5B | ||
| Q3 24 | $44.8M | — | ||
| Q2 24 | $93.7M | $1.4B | ||
| Q1 24 | $52.9M | — |
| Q4 25 | $44.7M | — | ||
| Q3 25 | $34.2M | — | ||
| Q2 25 | $33.9M | — | ||
| Q1 25 | $33.6M | — | ||
| Q4 24 | $33.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
| Q4 25 | $-271.1M | $7.3B | ||
| Q3 25 | $-274.1M | — | ||
| Q2 25 | $-354.6M | $6.1B | ||
| Q1 25 | $-341.8M | — | ||
| Q4 24 | $-326.4M | $5.5B | ||
| Q3 24 | $-292.3M | — | ||
| Q2 24 | $-241.3M | $4.3B | ||
| Q1 24 | $-201.4M | — |
| Q4 25 | $226.8M | $8.7B | ||
| Q3 25 | $233.9M | — | ||
| Q2 25 | $185.2M | $7.2B | ||
| Q1 25 | $200.2M | — | ||
| Q4 24 | $226.3M | $6.2B | ||
| Q3 24 | $238.5M | — | ||
| Q2 24 | $292.4M | $4.8B | ||
| Q1 24 | $256.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.6M | $323.3M |
| Free Cash FlowOCF − Capex | — | $322.4M |
| FCF MarginFCF / Revenue | — | 13.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 0.37× |
| TTM Free Cash FlowTrailing 4 quarters | — | $594.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.6M | $323.3M | ||
| Q3 25 | $-14.7M | — | ||
| Q2 25 | $-20.2M | $361.8M | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | $41.9M | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.2M | $-124.7M | ||
| Q1 24 | $-38.2M | — |
| Q4 25 | — | $322.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.2M | $356.6M | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | $40.9M | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.6M | $-125.5M | ||
| Q1 24 | $-38.2M | — |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | -78.7% | 20.1% | ||
| Q1 25 | -106.5% | — | ||
| Q4 24 | -107.0% | 3.0% | ||
| Q3 24 | -212.2% | — | ||
| Q2 24 | -164.4% | -13.9% | ||
| Q1 24 | -136.5% | — |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 2.0% | 0.1% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 0.37× | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
